Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 20;8(43):40613-40621.
doi: 10.1021/acsomega.3c05441. eCollection 2023 Oct 31.

Imidazo[1,2- a]pyrimidine as a New Antileishmanial Pharmacophore against Leishmania amazonensis Promastigotes and Amastigotes

Affiliations

Imidazo[1,2- a]pyrimidine as a New Antileishmanial Pharmacophore against Leishmania amazonensis Promastigotes and Amastigotes

Ravinder Kumar et al. ACS Omega. .

Abstract

Leishmania poses a substantial threat to the human population all over the globe because of its visceral and cutaneous spread engendered by all 20 species. Unfortunately, the available drugs against leishmania are already hobbled with toxicity, prolonged treatment, and increasing instances of acquirement of resistance. Under these grave circumstances, the development of new drugs has become imperative to keep these harmful microbes at bay. To this end, a Groebke-Blackburn-Bienaymé multicomponent reaction-based library of different imidazo-fused heterocycles has been synthesized and screened against Leishmania amazonensis promastigotes and amastigotes. Among the library compounds, the imidazo-pyrimidine 24 has been found to be the most effective (inhibitory concentration of 50% (IC50) < 10 μM), with selective antileishmanial activity on amastigote forms, a stage of the parasite related to human disease. The compound 24 has exhibited an IC50 value of 6.63 μM, being ∼two times more active than miltefosine, a reference drug. Furthermore, this compound is >10 times more destructive to the intracellular parasites than host cells. The observed in vitro antileishmanial activity along with suitable in silico physicochemical and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of compound 24 reinforce the imidazo-pyrimidine scaffold as a new antileishmanial pharmacophore and encourage further murine experimental leishmaniasis studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Imidazo-pyridine-based molecules having antileishmanial activity.
Scheme 1
Scheme 1. General Synthetic Protocol for the Formation of Imidazo-Fused Heterocycles.
Figure 2
Figure 2
Antileishmanial activity and cytotoxicity of imidazo-pyridine analogues (in μM). Pro and ama mean promastigotes and amastigotes, respectively, of L. amazonensis (L.A.). Cytotoxicity is the toxic effect on murine macrophages. These results correspond to the average of three experiments performed in duplicate.
Figure 3
Figure 3
Antileishmanial activity and cytotoxicity of compounds 13 and 14 (in μM). Pro and ama mean promastigotes and amastigotes, respectively, of L. amazonensis (L.A.). Cytotoxicity is the toxic effect on murine macrophages. These results correspond to the average of three experiments performed in duplicate.

References

    1. WHO 2023. Epidemiological situation. http://www.who.int/leishmaniasis/burden/en/ (accessed May 2023).
    1. Ruiz-Postigo J. A.; Grouta L.; Saurabh J.. 2020. Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators. https://www.who.int/publications-detail-redirect/who-wer9525 (accessed May 2023).
    1. Carvalho S. H.; Frézard F.; Pereira N. P.; Moura A. S.; Ramos L. M. Q. C.; Carvalho G. B.; Rocha M. O. C. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment. Trop. Med. Int. Health 2019, 24, 380–391. 10.1111/tmi.13210. - DOI - PubMed
    1. Chakravarty J.; Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opini. Pharmacother. 2019, 20, 1251–1265. 10.1080/14656566.2019.1609940. - DOI - PubMed
    1. Elmahallawy E. K.; Agil A. Treatment of leishmaniasis: a review and assessment of recent research. Curr. Pharmaceutical Design 2015, 21, 2259–2275. 10.2174/1381612821666141231163053. - DOI - PubMed